Salute e Benessere

Aino Health AB (publ): interim report january-june 2024

This document in English is a translation of the original in Swedish. In case of any discrepancy, the Swedish original will prevail.Extending contracts. Improved cash flow. January – June 2024• Net sales were KSEK 12 230 (11 971) • Profit/loss after financial items was KSEK -4 960 (-5 598)• Earnings per share were SEK -0,1 (-0,1)April – June 2024• Net sales were KSEK 6 236 (5 791)• Profit/loss after financial items was KSEK -2 017 (-2 807)• Earnings per share...
Nasdaq GlobeNewswire
16/08/2024

Essity's targets to reach net-zero emissions validated by Science Based Targets…

"Climate change is one of the defining issues of our time, and Essity has made a firm commitment to achieve net zero emissions by 2050. Our progress is driven by a sense of urgency throughout the organization, together with a strong innovation focus, and collaboration with customers, partners, and suppliers." says Magnus Groth, President and CEO of Essity. "Climate change is one of the defining issues of our time, and Essity has made a firm commitment to achieve net zero emissions…
PR Newswire
16/08/2024

NEXSTIM PLC HALF-YEAR REPORT JANUARY 1 – JUNE 30, 2024 (UNAUDITED)

Company announcement, Helsinki, August 16, 2024 at 9 am (EEST) NEXSTIM PLC HALF-YEAR REPORT JANUARY 1 – JUNE 30, 2024 (UNAUDITED)NEXSTIM CONTINUED TO GROW AND IMPROVED ITS PROFITABILITY IN THE FIRST HALF OF THE YEARThe figures in parentheses refer to the previous year's comparative period, unless otherwise stated. January–June 2024 in briefThe company's net sales were EUR 3.2 million (2.5), with an increase of 26.9 %Net sales growth adjusted for currency exchange...
Nasdaq GlobeNewswire
16/08/2024

Bavarian Nordic Submits Data to EMA to Extend Mpox/Smallpox Vaccine Approval to…

Interim results from clinical study show non-inferiority of immune responses from mpox/smallpox vaccination in adolescents and similar safety profile compared to adults, supporting the extension of current approval in Europe later in 2024.COPENHAGEN, Denmark, August 16, 2024– Bavarian Nordic A/S (OMX: BAVA) has submitted clinical data to the European Medicines Agency (EMA) to support the extension of the IMVANEX ®(MVA-BN ® ) smallpox and mpox vaccine indication to include adolescents...
Nasdaq GlobeNewswire
16/08/2024

Navamedic Q2 and H1 2024: Stable growth continues and is supported by a new…

In June, Navamedic signed a license and supply agreement with Orion Corporation (Orion) to market and sell Flexilev® and OraFID® in Europe. This agreement represents a major milestone in Navamedic's commercialisation strategy for Flexilev®. Orion has paved the way for Parkinson's disease treatment in Europe, making it a strong commercial partner for Navamedic. In June, Navamedic signed a license and supply agreement with Orion Corporation (Orion) to market and sell Flexilev ®and OraFID…
PR Newswire
16/08/2024

Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and…

Record Total Revenues of $236 million for the first six months of 2024, an over ten-fold increase compared to same period in 2023Product revenues for the first six months were $66 million, a 190% increase from the same period last year, with Q2 product revenues contributing $53 millionLicense and other revenues for the first six months increased to $170 million, with Q2 license and other revenues contributing $145 million Adjusted EBITDA in the first six months was $64 million,...
Nasdaq GlobeNewswire
15/08/2024

OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual…

LONDON and NEW YORK, Aug.15, 2024(GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announced today the company will participate in the H.C. Wainwright 4th Annual...
Nasdaq GlobeNewswire
15/08/2024

Global Blood Pressure Cuffs Market to Reach USD 1,399 Million by 2029: Key…

Browse in-depth TOC on "Blood Pressure Cuffs Market" Browse in-depth TOC on "Blood Pressure Cuffs Market" 268 - Tables49 - Figures270 - Pages Competitive Landscape and Major Players The blood pressure cuffs market is competitive, with OMRON Corporation ( Japan ), Baxter International Inc. (US), and McKesson Corporation (US) being the leading players. These companies employ a mix of organic and inorganic growth strategies, including expansions, agreements, and...
PR Newswire
15/08/2024

Isostatic Pressing Market worth $9.9 Billion by 2029 - Exclusive Report by…

Browse in-depth TOC on "Isostatic Pressing Market" Browse in-depth TOC on "Isostatic Pressing Market" 200 – Tables 67 – Figures 235 – Pages Isostatic Pressing Market Report Scope: The hot isostatic pressing (HIP) segment is to grow with a higher CAGR during the forecast period. HIP systems combine the standard HIP cycles with various heat treatment processes. Such systems have very wide applications in powder metallurgy operations across the world, since they...
PR Newswire
15/08/2024

DNA Sequencing Market to Be Worth $21.30 Billion by 2031--Exclusive Report by…

Download Sample Report Now- https://www.meticulousresearch.com/download-sample-report/cp_id=5992 Download Sample Report Now-https://www.meticulousresearch.com/download-sample-report/cp_id=5992 DNA sequencing is a technology used to sequence the orientation of nucleotides in genetic material. This technology enables the sequencing of DNA more precisely, allowing researchers to decode genetic information at an unprecedented scale and speed. This market's growth is driven by factors...
PR Newswire
15/08/2024

Cresilon Receives FDA Clearance for TRAUMAGEL

Cresilon's revolutionary plant-based hemostatic gel technology is designed to stop and control life-threatening bleeding in a matter of seconds when applied to a wound at the point of care. TRAUMAGEL, which utilizes Cresilon's proprietary hydrogel technology, is a first-of-its-kind hemostatic medical device with FDA clearance for temporary external use in moderate to severe bleeding. Cresilon's revolutionary plant-based hemostatic gel technology is designed to stop and control…
PR Newswire
15/08/2024

Orion Corporation: Managers' transactions – Hao Pan

ORION CORPORATIONMANAGERS' TRANSACTIONS15 AUGUST 2024 at 15.30 EEST Orion Corporation: Managers' transactions – Hao Pan Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.Orion Oyj - Managers' Transactions ____________________________________________ Person subject to the notification...
Nasdaq GlobeNewswire
15/08/2024

Oculis Appoints Sharon Klier, M.D., M.S., M.P.H. as Chief Development Officer

Dr. Klier has over 20 years' experience developing and executing global clinical development strategies that have supported product approvals and successful launches in retina and corneal diseases. Before joining Oculis, she served as Chief Development Officer, Head of Ophthalmology at UNITY Biotechnology, where she played a key role in driving forward UNITY's pipeline. Prior to that, Dr. Klier held roles of increasing responsibility at several companies including Quark, Allergan, ISTA and...
Nasdaq GlobeNewswire
15/08/2024

uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of…

uniQureN.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the first patient has been dosed in a Phase I/IIa clinical trial of AMT-191 for the treatment of Fabry disease, a rare, inherited genetic disease. The Phase I/IIa study is a multi-center, open-label trial being conducted in the United States with two dose-escalating cohorts assessing the safety, tolerability and early signs of efficacy of...
Nasdaq GlobeNewswire
15/08/2024

MolecuLight Secures $11.7 Million in Financing to Accelerate Global Expansion

"MolecuLight's innovative technology has the potential to significantly improve patient outcomes and offers compelling benefits for all healthcare system stakeholders," said Guillermo Freire, Senior Vice-President, Mid-Market Group, EDC. "We are excited to invest in MolecuLight as they accelerate commercialization. EDC is focused on supporting emerging Canadian innovators in critical sectors essential for the future. This investment reflects our belief in innovation and progress…
PR Newswire
15/08/2024

European Medicines Agency Confirms Acceptance of Marketing Application for…

The approvals process is anticipated to be completed in the third quarter of 2025 Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency (EMA) has accepted a Marketing Authorization Application for...
Nasdaq GlobeNewswire
15/08/2024

Sleep Aid Supplement Market to Reach $11.8 Billion, Globally, by 2034 at 5.1%…

Download PDF Brochure: https://www.alliedmarketresearch.com/request-sample/A323764 Download PDF Brochure: https://www.alliedmarketresearch.com/request-sample/A323764 Prime Determinants of Growth The sleep aid supplements market is witnessing strong growth owing to several key factors. Firstly, rising awareness about the importance of sleep for overall health and well-being has spurred demand for products that can help improve sleep quality. In addition, lifestyle factors such as...
PR Newswire
15/08/2024

Implantica announces another landmark real-world RefluxStop™ study demonstrating…

Dr. Zehetner said, "It's remarkable to see such profound clinical improvements in all patients despite the preoperative IEM condition found in most of the patients in this study. All 40 patients had significantly improved or fully resolved reflux symptoms with minimal side effects. Based on about 150 RefluxStop cases I've performed over the past 4 years, it's clear RefluxStop has the potential to reform how we treat severe GERD patients, especially with ineffective esophageal motility where…
PR Newswire
15/08/2024

NANOFORM COLLABORATES WITH TAKEDA ON THEIR PLASMA-DERIVED THERAPY DEVELOPMENT

"Direct nanoforming of biologics is a promising new approach to allow more life-changing large-molecule medicines to reach the market," commented Dr. Edward Haeggström, CEO of Nanoform. "We look forward to entering in vivo studies together with Takeda and expanding our already very positive relationship." "Direct nanoforming of biologics is a promising new approach to allow more life-changing large-molecule medicines to reach the market," commented Dr. Edward…
PR Newswire
15/08/2024

Bioretec Ltd's half-year report January-June 2024: RemeOs™ trauma screw…

April-June 2024 in brief April- June 2024in brief January- June 2024in brief Key figures Key events in April- June 2024 Alan Donze, CEO of Bioretec Ltd: "Bioretec's controlled launch plan was designed to systematically gather surgeon feedback and clinical evidence from selected hospitals. In the first half of the year, we received invaluable positive feedback from surgeons regarding the user experience. More importantly, all treated patients experienced the...
PR Newswire
15/08/2024

Ultimovacs ASA: Invitation to second quarter 2024 results webcast presentation

Oslo, August 15, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, invites to a webcast presentation of its second quarter 2024 results on Wednesday, August 21, 2024.The presentation can be followed as a live webcast accessed through a link on www.ultimovacs.com at 14:00 CET on Wednesday, August 21, 2024, and is scheduled to conclude at 14:55 CET. The webcast presentation will be available on the Ultimovacs...
Nasdaq GlobeNewswire
15/08/2024

Zealand Pharma Announces Financial Results for the First Half of 2024

Company announcement - No. 39 / 2024 Zealand Pharma Announces Financial Results for the First Half of 2024 Very strong progress across R&D pipeline followed by substantial capital raise enabling further investments to accelerate the development programs for wholly owned obesity assets. Extremely encouraging weight loss and tolerability data announced with long-acting amylin analog petrelintide from MAD Part 2 (16-week trial)Impressive data from Boehringer Ingelheim's Phase 2...
Nasdaq GlobeNewswire
15/08/2024

Exosomes Skincare Market Size to Grow USD 674.2 Million by 2030 at a CAGR of…

Get Free Sample @ https://reports.valuates.com/request/sample/QYRE-Auto-2N13078/Global_Exosomes_Skincare_Market Get Free Sample @ https://reports.valuates.com/request/sample/QYRE-Auto-2N13078/Global_Exosomes_Skincare_Market Major Factors Driving the Growth of Exosomes Skincare Market: The market for exosome skincare products is expanding significantly due to advances in biotechnology and rising consumer awareness of cutting-edge skincare products. Nanoscale extracellular vesicles...
PR Newswire
14/08/2024

Anesthesia Drugs Market Size to Grow USD 5152.6 Million by 2030 at a CAGR of…

Get Free Sample @ https://reports.valuates.com/request/sample/QYRE-Auto-0V13533/Global_Anesthesia_Drugs_Market Get Free Sample @ https://reports.valuates.com/request/sample/QYRE-Auto-0V13533/Global_Anesthesia_Drugs_Market Major Factors Driving the Growth of Anesthesia Drugs Market: Thanks to improvements in anesthetic techniques and an increase in surgical operations globally, the anesthesia drugs market is expanding rapidly. The need for efficient anesthetic medications is being...
PR Newswire
14/08/2024
Altri  Comunicati